Abstract
HIV-related enacted stigma and social problems may increase risk for depression and/or behavioral problems among adolescents and young adults with perinatal HIV(AYA-PHIV), yet few studies have explored stigma in AYA-PHIV residing in low-to-middle income regions, including Southeast Asia. We assessed HIV-related enacted stigma and social problems in AYA-PHIV who participated in the RESILIENCE study (clinicaltrials.gov identification: U19AI53741) in Thailand and Cambodia using specific questions during structured in-person interviews. Depression was measured by the Child Depression Inventory for children <15 years, or the Center for Epidemiologic Studies Depression Scales for youth ≥15 years); behavioral problems were measured by the Child Behavior Checklist (CBCL-caregiver report). Among 195 AYA-PHIV (median age 16.9 years), 25.6% reported a lifetime experience of enacted stigma, while 10.8% experienced social problems due to HIV infection. The frequency of depressive symptoms was nearly two-fold higher among AYA-PHIV with compared to those without HIV-related enacted stigma (34.7% vs. 16.0%, p = 0.005). Caregiver-reported behavioral problems were detected in 14.6% of all AYA-PHIV, with no differences between those with and without HIV-related enacted stigma. Low household income and caregiver mental health problems were independent risk factors for depressive symptoms; HIV-related enacted stigma was also associated with increased risk, warranting targeted services to support AYA-PHIV.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 246-256 |
| Number of pages | 11 |
| Journal | International Journal of STD and AIDS |
| Volume | 32 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The PREDICT study was sponsored by the National Institute of Allergy and Infectious Disease (NIAID), Grant number U19 AI053741, Clinical trial.gov identification number NCT00234091. Antiretroviral drugs for PRE- DICT were provided by ViiV Healthcare (AZT, 3TC), Boehringer Ingelheim (NVP), Merck (EFV), Abbott (RTV) and Roche (NFV). The neurodevelopment work was supported by initial funds by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, and later funded by R01MH089722. The Resilience study funded by the National Institute of Mental Health, National Institutes of Health, Grant number R01MH102151.
Keywords
- Adolescent
- behavioral problem
- depressive symptoms
- enacted stigma
- perinatal HIV infection
- young adults
ASJC Scopus subject areas
- Dermatology
- Public Health, Environmental and Occupational Health
- Pharmacology (medical)
- Infectious Diseases
